Session Abstract – PMWC 2022 Silicon Valley


Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.

Sessions:

  • 4th Generation Sequencing Technologies & Genome Mapping Systems
    - Barrett Bready, Nabsys
    - Alka Chaubey, Bionano Genomics
  • Long-Read Sequencing Technologies
    - Steve Turner, PacBio
  • Single Cell Genomics
    - Michael Schnall-Levin, 10x Genomics
  • Spatial Transcriptomics
    - Jason T. Gammack, Resolve Biosciences
  • Pathogen Identification
    Session Chair: Charles Chiu, UCSF
    - Todd Dickinson, Arc Bio
    - Philip Stevens, Noscendo
  • ML/AI for Diagnosis & Prognosis
    - Amrie Grammer, Ampel BioSolutions
  • Modern Technologies for Pathogen Identification + AI
    Session Chair: Sivan Bercovici, Karius Dx
  • Proteogenomics
    - Nigel Beard, Encodia
  • Advances Proteomics - Stratifying Cardiovascular Risk to Decrease Cost of Care
    Session Chair: Roy Smythe, SomaLogic
    - Matthias Kleinz, UPMC
  • Leveraging Immune System Diagnostics to Improve Disease Outcomes
    Session Chair: Kathy Kamath, Serimmune, Inc
    - Millennia Lytle, Mymee
    - Noah Nasser, Serimmune, Inc
  • Evolving Alzheimer’s Disease Therapeutics with Neuro Diagnostic Therapies
    Session Chair: Kevin Hrusovsky, Quanterix
    - Charlotte Teunissen, Amsterdam UMC
    - Henrik Zetterberg, University of Gothenburg
    - Nicholas Ashton, University of Gothenburg
  • PMWC Showcase (NCI)
    - Michael Cardone, Eutropics Pharmaceuticals
    - Robert Meltzer, Fluent BioSciences
    - Cynthia Taylor Lawley, Olink Proteomics
    - Brian McKelligon, Akoya Biosciences

 Session Chair Profile

M.D., Ph.D., Professor, Laboratory Medicine and Medicine/Infectious Diseases, UCSF

Biography
Charles Chiu, M.D./Ph.D. is a Professor at UCSF, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. Chiu currently leads a translational research laboratory focused on clinical metagenomic sequencing assay development for infectious diseases and genomic investigation and surveillance of emerging pathogens, including the SARS-CoV-2 coronavirus. He also uses RNA-Seq transcriptome profiling to develop predictive models using machine learning for host response-based diagnosis of COVID-19 and other infections. Chiu’s work is supported by funding from the National Institutes of Health (NIH), Department of Defense, US Centers for Disease Control and Prevention (CDC), philanthropy, and the California Initiative to Advance Precision Medicine. He has authored more than 100 peer-reviewed publications (>20 on COVID-19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Danaher Dx, Biomesense, and Flightpath.


 Session Chair Profile

Ph.D., Senior Director of R&D, Serimmune, Inc

Biography
Dr. Kamath is a founding scientist at Serimmune, Inc. Her expertise in therapeutic and diagnostic development has been essential to Serimmune’s Serum Epitope Repertoire Analysis (SERA) platform. SERA combines the power of bacterial display peptide library technology with next-generation sequencing and bioinformatics to profile antibody repertoires and identify and map antibody-based biomarkers of infections, autoimmunity and cancer. Once discovered, all the biomarkers can be assayed simultaneously from a single test, potentially reducing time to diagnosis or providing insights into the cause of undiagnosed disease. Prior to her work at Serimmune, Dr. Kamath worked on the development of cancer companion diagnostic and diagnostic assays at Agilent Technologies as well as modified therapeutic monoclonal antibodies (ProbodiesTM) at CytomX Therapeutics. She received her Ph.D. from University of California, Santa Barbara with an emphasis on cancer biology and therapy.


 Session Chair Profile

M.B.A, B.S, President, Chairman & CEO, Quanterix Corporation; Founder & Chairman, Powering Precision Health

Biography
Kevin Hrusovsky has dedicated his 30-year career to leading disruptive medical technology companies and shepherding a global movement to transform healthcare to Precision Health. He created Powering Precision Health foundation, an internationally renowned non-profit promoting a new era of medicine using biomarker innovation to achieve precision medicine. Kevin has always been committed to accelerating adoption and value creation for many “game changing” non-invasive early detection technologies for Oncology, Neurodegeneration and Cardiology which are transforming drug development and disease prevention. Before Quanterix, he was CEO of Caliper Life Sciences, and Zymark Corporation, as well as, President of Life Sciences at PerkinElmer. He is the recipient of several distinguished awards including the 2019 EY Entrepreneur of the Year®, the 2018 Lifetime Achievement Award for Leadership and the E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University.


 Session Chair Profile

Ph.D., Chief Technology Officer, Karius

Biography
Sivan Bercovici is the Chief Technology Officer at Karius, where he leads the computational and data efforts aimed at unlocking the clinical value in the microbiome data. Throughout his career, Sivan has developed novel machine-learning methods and analytical platforms that address broad challenges in genetics and the study of human disease. Prior to Karius, Sivan was a co-founder and Chief Technology Officer at Lifecode. He obtained his Ph.D. in Computer Science from Technion – Israel Institute of Technology and completed his postdoctoral research at Stanford University, as part of Stanford’s Artificial Intelligence Laboratory.


 Session Chair Profile

M.D., CEO, SomaLogic

Biography
Roy Smythe, M.D., joined SomaLogic in November 2018 as Chief Executive Officer. Throughout the course of his career, Dr. Smythe has been an internationally recognized surgeon, biomedical scientist, academician, health system administrator and healthcare business entrepreneur. Dr. Smythe came to SomaLogic from Royal Philips, where he served as Global Chief Medical Officer for Strategy and Partnerships. Before joining Philips, he served as Chief Medical Officer at Valence Health, a Chicago-based healthcare company. He held the same title previously at AVIA, a healthcare technology accelerator. A highly sought-after lecturer and the author of more than 300 papers, abstracts and essays in academic, literary and humanities publications, Dr. Smythe is also currently a member of more than 20 U.S. national learned societies.


 Speaker Profile

Ph.D., Co-Founder and CEO, Resolve Biosciences

Biography
Jason T. Gammack brings more than 25 years of life sciences industry experience and has developed successful product and customer engagement strategies for some of its preeminent biotechnology brands. He recently served as Chief Commercial Officer at Inscripta, where he oversaw sales, marketing, business development, and customer support for the company’s CRISPR-enabled Onyx™ Digital Genome Engineering platform. Before that, he was Vice President of the Life Science Business at QIAGEN, where he led the life science portfolio and go-to-market strategy. Earlier in his career, Gammack developed commercialization growth strategies at Ingenuity Systems, a leading bioinformatics company acquired by QIAGEN in 2013. He has also held senior leadership roles at Sigma-Aldrich, Invitrogen/Life Technologies, Affymetrix, and Promega Corporation.


 Speaker Profile

N.D., M.P.H., Head of Coaching, Mymee, Inc.

Biography
At Mymee, Dr. Lytle manages the coaching program, including all care delivery. She merges her education, clinical practice and research experience in the fields of naturopathic medicine, functional nutrition and chronic disease epidemiology to supervise all client consultations, develop coaching protocols, collect data and review RWE, participate in clinical trials and collaborate internally to build and execute program strategy. Dr. Lytle is a licensed naturopathic doctor, epidemiologist and nutrition specialist dedicated to preventing and reversing the epidemic of chronic disease. She earned her 4-year post grad ND from the Canadian College of Naturopathic Medicine and a Master's in Public Health (MPH) in Hamburg, Germany. In addition to 15 years of private practice, Millie is a published researcher and conference speaker.

Talk
Mymee and Serimmune Case Collaborations
Case analysis and outcomes will be presented on joint Mymee and Serimmune clients with particular focus on positive antibodies, client symptoms and diagnoses, and health related quality of life and disease improvement results.


 Speaker Profile

President & CEO, Serimmune

Biography
Noah Nasser is Serimmune's Chief Executive Officer. With more than twenty-five years of experience in biotechnology, Noah brings a broad background in the development and commercialization of novel technology to advance human health. Noah joins Serimmune from San Diego biotechnology company, Human Longevity, Inc., a direct-to-consumer health screening organization combining proprietary imaging and genetic technologies, where he was chief commercial officer. Prior to Human Longevity, Noah was chief commercial officer at Counsyl, a market leading genetic testing laboratory focused on women's health applications, including non-invasive prenatal testing, expanded carrier screening and hereditary cancer screening. Noah led Counsyl's commercial team through its acquisition in 2018 by Myriad Genetics, Inc. He previously held senior leadership positions at San Diego-based biotechnology company AltheaDx, and San Carlos-based Verinata Health, a leader in non-invasive prenatal testing (NIPT), where he led his team through the company's acquisition by Illumina in 2013.

Talk
Applications of Functional Antibody Repertoire beyond Research
Serimmune has developed a novel technology for assessing personal immune response through antibody repertoires. We will describe the application of this technology in the clinical space for diagnosis of immune agents in diverse diseases and syndromes as well as how these data may lead to better health outcomes in the future.


 Speaker Profile

PROF.DR.IR., Professor, Amsterdam UMC

Biography
Charlotte Teunissen’s drive is to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, often by –omics methods, followed by biomarker assay development and analytical validation, and lastly, extensive clinical validation and implementation of novel biomarkers in clinical practice. She has extensive expertise with assay development on state of the art technologies, such as mass spectrometry and antibody-based arrays for biomarker discovery, ultrasensitive immunoassays, and in in implementation of vitro diagnostic technologies for clinical routine lab analysis. She is responsible for the large well-characterised biobank of the Amsterdam Dementia cohort, containing >5200 paired CSF and serum samples of individuals visiting the memory clinical of the Alzheimer Center Amsterdam (a.o. controls, patients with Alzheimer, Frontotemporal, Lewy Bodies).To ensure the quality of the biosamples, the group studies pre-analytical effects, which are key to implementation. Charlotte is leading several collaborative international biomarker networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization and Blood Based Biomarkers consortia. She is the coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into innovative strategies to develop dementia biomarkers (10 academic centers + 10 non-academic centers), and the JPND bPRIDE project, that aims to develop targeted blood based biomarker panels for early differential diagnoses of specific dementias and is a collaborative project between 7 European and 1 Australian centers.


 Speaker Profile

Ph.D., CEO, Arc Bio

Biography
Dr. Dickinson has been CEO of Arc Bio and Dovetail Genomics since 2014. He earned degrees in chemistry and theology from St. Olaf College, and a Ph.D. in analytical chemistry at Tufts University under the direction of Professor David Walt. Dr. Dickinson helped start Illumina in 1998 based on ideas conceived from his doctoral research in the Walt lab. During his 12-year tenure, Dr. Dickinson helped establish the product development processes at Illumina and led several of the earliest project teams. As Director of Product Marketing at Illumina, his teams carried out over 60 product launches in a two-year period and achieved triple-digit growth across several product lines. In 2011 he joined BioNano Genomics to lead the commercialization of a novel nanochannel array platform.  During his tenure at BioNano, Dr. Dickinson served as Vice President of Product Development, and subsequently as Vice President of Global Commercial Operations, and led the company’s worldwide launch of its flagship product offering, the Irys™ system.


 Speaker Profile

Ph.D., COO/CSO, AMPEL BioSolutions

Biography
Dr. Grammer is an internationally recognized scientist and successful entrepreneur, having founded and managed AMPEL successfully for over 5 years. Dr. Grammer was elected to the class of 2021 for SIBF (Society of International Business Fellows), an organization of 1,400 individuals in 45 countries worldwide. She was also awarded a Virginia SBIG grant for AMPEL's first investment round. She is a second term board member of Virginia Bio.Before co-founding AMPEL in 2013, Dr. Grammer spent over 20+ years in genomics and managed more than 15 National Institute of Health (NIH) scientific teams and a highly productive NIH laboratory. Dr. Grammer received multiple awards for her team's work comparing genes expressed in patients compared with healthy individuals, including the prestigious NIH Director's Award as well as mentoring awards from the American Association of Immunologists. She has published over 75 articles on her scientific research.

Talk
ML/AI for Diagnosis & Prognosis


 Speaker Profile

Ph.D., CEO, Noscendo GmbH

Biography
Dr. Philip Stevens studied bioinformatics at the University of Tübingen from 2007 to 2012 and earned his doctorate in molecular biology/ bioinformatics from the Max Perutz Laboratories, Vienna a joint Institution of the Medical University of Vienna and the University of Vienna in a collaboration with the Fraunhofer IGB, Stuttgart in 2016. He specialized in algorithmic solutions for pathogen detection in the context of clinical metagenomics utilizing cell-free DNA. From 2017 on, he served as CEO of Noscendo GmbH, a world leader in pathogen detection from clinical specimens using proprietary bioinformatics and newest sequencing technologies. In 2018 he was recognized as “Innovators under 35” by MIT Technology Review in Germany. In addition, he was named “entrepreneur with the most social impact”. In 2019 he was further awarded “Innovators under 35 in Europe” by MIT-Technology Review.


 Speaker Profile

M.D., Ph.D., Professor, Head of Department, Psychiatry and Neurochemistry, University of Gothenburg

Biography
Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL and is a Key Member of the Hong Kong Center for Neurodegenerative Diseases. His main research focus and clinical interest are fluid biomarkers for brain diseases, neurodegenerative disease in particular.

Talk
Update on Blood Biomarkers for Neurodegenerative Dementias


 Speaker Profile

Ph.D., Assistant Professor of Neurochemistry, University of Gothenburg, Sweden

Biography
Dr. Ashton has a decade of experience in biofluid analysis and assay development for Alzheimer’s disease and related disorder which ranges from discovery mass spectrometry methods to ultra-sensitive immunoassays development. Recently, this has seen the success of assays specific for phosphorylated tau and neurofilament light, which being evaluated for clinical routine across Europe and inclusion criterion for clinical trials targeting dementia. Dr. Ashton was the 2021 recipient for the Queen Silvia prize for Alzheimer’s research in Sweden and published >100 original research articles in fluid biomarker for neurogenerative diseases.

Talk
Ultrasensitive Biomarkers for Amyloid Burden


 Speaker Profile

Ph.D., SVP R&D, 10x Genomics

Biography
Michael Schnall-Levin has been at the company since its inception and today serves as Senior Vice President, R&D. Before joining 10x Genomics, Michael was a NSF postdoctoral fellow with Eric Lander at the Broad Institute, where he worked on developing novel applications of DNA sequencing technologies. Prior to that, Michael worked at Foundation Medicine, where he developed some of the early algorithms to accurately detect mutations in patient tumor samples. Michael earned his Ph.D in Mathematics from MIT with Bonnie Berger, where he was both a Hertz fellow and NDSEG fellow, and his B.A. in Physics from Harvard College.


 Speaker Profile

Ph.D., Director of Advanced Projects, Fluent BioSciences

Biography
Robert brings to Fluent BioSciences over a decade of experience in innovation, development, and commercialization of ultrasensitive molecular diagnostics. He has developed methods and instrumentation for rapid bacterial identification from complex mixtures, targeted cancer diagnostics from liquid biopsy, and single cell transcriptomics. He holds degrees in Biomedical Engineering from Texas A&M University and Molecular Physiology and Biophysics from Baylor College of Medicine.


 Speaker Profile

Ph.D., Director, Population Health , Olink

Biography
Cindy is passionate about innovation to make genetic and multi-omic technologies easier and cheaper to measure. She sees such innovation as pivotal to lower the barrier of entry for implementing scalable, reproducible solutions advancing individualized medicine and health equity. In over 14 years at Illumina, she helped develop genetic and genomic based solutions to advance the understanding of genetic risk and holds several awards for her genetic work for Excellence in Technology Transfer. She joined Olink soon after the launch of the Explore Platform that leverages next generation sequencing as a high throughput proteomic readout to measure ~3,000 proteins in just 6uL of sample. Ask her about how high throughput proteomics are helping translate the impact our genetics has on more real time health.

Talk
Framework for Target Discovery toward Multi-omic Supported Precision Medicine
Massive advances in genetic discoveries over the past decade are due in large part to the drastic drop in sequencing pricing and increased availability of academic-, industry- and government- affiliated large cohorts and biobanks. Advances in proteomics are now enabling us to translate the impact our genetics has on more real-time health.


 Speaker Profile

M.D., Founder & CEO, Nabsys

Biography
Dr. Bready was founding CEO of Nabsys in 2005, helped lead development of the core technologies, and raised $100 million in venture financing to support the company’s growth. His technical and business leadership has resulted in the successful development and commercialization of HD-Mapping™, electronic high-definition whole-genome mapping. Dr. Bready is an adjunct professor at Brown University where he lectures on the rapidly evolving business of biotechnology. He serves as a commissioner of the I-195 Redevelopment District Commission, a major land redevelopment initiative in downtown Providence, RI with a focus on life sciences and other high-technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year, and in 2018, a career achievement award from the Warren Alpert Medical School of Brown University. Dr. Bready received an M.D. and an Sc.B. in physics from Brown University, both as part of Brown’s Program in Liberal Medical Education (PLME).


 Speaker Profile

Ph.D., CEO, Eutropics Pharmaceuticals

Biography
Michael Cardone leads Eutropics’ scientific efforts to achieve corporate milestones. The company develops novel predictive diagnostic tools for personalized medicine. The new platform measures cellular mechanisms that regulate apoptosis. This platform is providing compositions and methods for assessing therapeutic approaches for blood and solid cancers and providing personalized treatments for individual patients. His experience includes 20 years of scientific and business management at early to mid-stage biotech companies. Prior to Eutropics, he was a scientific co-founder of publicly traded Merrimack Pharmaceuticals, a Cambridge, MA-based company where he worked with the starting team to develop the oncology program. Prior to this, he worked at MIT developing tools for small molecule drug target identification and validation. He received a Ph.D. in cell biology at UCSF and completed post-doctoral studies in apoptosis signaling at the Burnham Institute in La Jolla, CA.

Talk
Prediction of Tumor Cell Response to Therapy
Eutropics' unique panel of antibodies, “PRIMABs”, enable detection of tumor cell mitochondrial priming, a key determinant of cancer responsiveness to treatments. The presence (or absence) of the critical pro-survival : pro-apoptotic protein complexes, is used as a predictive biomarker for personalized medicine. Such reagents have hitherto not been available.


 Speaker Profile

Ph.D., Senior Vice President, UMPC

Biography
Dr. Kleinz joined UPMC Enterprises in July 2017 to help the ITTC invest and commercialize innovative translational science by defining the true potential of new life science technologies, exploring optimal business models and strategies, and helping to form companies with a clear path to success. Prior to UPMC Enterprises, Dr. Kleinz spent nine years in management consulting at L.E.K. Consulting in its life sciences practice in Boston and London leading teams on over 70 strategic assignments for clients in the U.S., Europe, and Japan. Dr. Kleinz completed his PhD in the Clinical Pharmacology Unit of the University of Cambridge (UK), working on early stage discovery of G-protein-coupled receptor targets for hypertension, heart disease and metabolic syndrome and graduated from Justus Liebig University in Giessen (GER) with a doctorate in clinical veterinary medicine.


 Speaker Profile

Ph.D., Chief Technical Officer, Pacific Biosciences

Biography
Dr. Turner founded Pacific Biosciences (formerly Nanofluidics) and in 2004 secured its Series A funding. He was awarded a Ph.D. in Physics by Cornell University in 2000, where he worked with Prof. Harold Craighead to study the behavior of biomolecules in nano-fabricated structures. He was a member of the project team at Cornell which developed the technology now employed by Pacific Biosciences and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the technology to the scientific community. Dr. Turner’s undergraduate work was at the University of Wisconsin, Madison, where he received a Bachelor of Science in Applied Mathematics, Electrical Engineering and Physics. He is the author of over 50 scientific papers in fields ranging from DNA sequencing technology and biophysics to genomics and epigenomics. He is listed as the inventor on over 50 U.S. patents and numerous published patent applications. Dr. Turner was recipient of the MIT Technology Review “TR100” Award in 2003 and the University of Wisconsin Madison Distinguished Young Alumnus Award in 2008.


 Speaker Profile

Ph.D., Chief Technology Officer, Encodia

Biography
As Encodia's Chief Technology Officer, Dr Beard leads a talented and innovative team to develop and scale the product portfolio. Dr. Beard has a 20+ year track record of bringing transformative life sciences products to market. Experienced in strategic technology development raising over +$100M venture capital in cutting edge genomics, machine learning and 3D printing technologies that focused on precision and personalized products from consumer to multiomic platforms aimed at eradicating cancer. Most recently served as CTO and Senior Vice President (SVP) of Operations at Mission Bio, where he launched and scaled Tapestri, a platform for multiomic single cell analysis. Prior to that, he served as Chief Operating Officer (COO) and CTO at Feetz, Inc. He also held R&D leadership positions for Applied Biosystems and Life Technologies, managing $100M's in R&D spend for +1,500 scientists. He is an inventor on over 50 patents, launched over 40 products, and serves as an advisor/board member for other start-up companies.